GSK’s patent on lapatinib ditosylate revoked by IPAB
8th August, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July, 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on ground of non-compliance with S.3d alone on basis of no … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »Inventors, All Technologies Aren’t Worth Billions
31st July, 2011 - 6:23 pm
Categories:
Hi Tech Patent Commercialisation
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments
Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions
Read more »